Methods and compositions for treating hepatitis C virus

a technology for hepatitis c virus and compositions, applied in the field of methods and compositions for treating hepatitis c virus, can solve the problems of ribavirin alone being ineffective in reducing viral rna levels, ribavirin having significant toxic effects, and causing anemia, hemolysis, fatigue, etc., to inhibit hcv polymerase activity and determine the activity spectrum

Inactive Publication Date: 2005-06-09
SOMMADOSSI JEAN PIERRE +1
View PDF98 Cites 127 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0096] The β-D- and β-L-nucleosides of this invention may inhibit HCV polymerase activity. Nucleosides can be screened for their ability to inhibit HCV polymerase activity in vitro according to screening methods set forth more particularly herein. One can readily determine the spectrum of activity by evaluating the compound in the assays described herein or with another confirmatory assay.

Problems solved by technology

Thus, Ribavirin alone is not effective in reducing viral RNA levels.
Additionally, Ribavirin has significant toxicity and is known to induce anemia.
Unfortunately, the effects of IFN are temporary and a sustained response occurs in only 8%-9% of patients chronically infected with HCV (Gary L. Davis. Gastroenterology 18:S104-S114, 2000).
Side effects of combination therapy include hemolysis, flu-like symptoms, anemia, and fatigue.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating hepatitis C virus
  • Methods and compositions for treating hepatitis C virus
  • Methods and compositions for treating hepatitis C virus

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of 1′-C-methylriboadenine via 6-amino-9-(1-deox-(β-D-psicofuranosyl)purine

[0447] As another alternative method of preparation, the title compound could also be prepared according to a published procedure (J. Farkas, and F. Sorm, “Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine”, Collect. Czech. Chem. Commun. 1967, 32, 2663-2667. J. Farkas”, Collect. Czech. Chem. Commun. 1966, 31, 1535) (Scheme 7).

[0448] In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula I are prepared.

[0449] wherein:

R1R2R3X1X2YHHHHHHHHHHHNH2HHHHHNH-cyclopropylHHHHHNH-methylHHHHHNH-ethylHHHHHNH-acetylHHHHHOHHHHHHOMeHHHHHOEtHHHHHO-cyclopropylHHHHHO-acetylHHHHHSHHHHHHSMeHHHHHSEtHHHHHS-cyclopropylHHHHHFHHHHHClHHHHHBrHHHHHImonophosphateHHHHNH2monophosphateHHHHNH-acetylmonophosphateHHHHNH-cyclopropylmonophosphateHHHHNH-methylmonophosphateHHHHNH-ethylmonophosphateHHHHOHmonop...

example 2

Preparation of 2′-C-methylriboadenine

[0460] The title compound was prepared according to a published procedure (R. E. Harry-O'kuru, J. M. Smith, and M. S. Wolfe, “A short, flexible route toward 2′-C-branched ribonucleosides”, J. Org. Chem. 1997, 62, 1754-1759) (Scheme 8).

[0461] In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula II are prepared.

[0462] wherein:

R1R2R3X1X2YHHHHHHHHHHHNH2HHHHHNH-cyclopropylHHHHHNH-methylHHHHHNH-ethylHHHHHNH-acetylHHHHHOHHHHHHOMeHHHHHOEtHHHHHO-cyclopropylHHHHHO-acetylHHHHHSHHHHHHSMeHHHHHSEtHHHHHS-cyclopropylHHHHHFHHHHHClHHHHHBrHHHHHImonophosphateHHHHNH2monophosphateHHHHNH-acetylmonophosphateHHHHNH-cyclopropylmonophosphateHHHHNH-methylmonophosphateHHHHNH-ethylmonophosphateHHHHOHmonophosphateHHHHO-acetylmonophosphateHHHHOMemonophosphateHHHHOEtmonophosphateHHHHO-cyclopropylmonophosphateHHHHSHmonophosphateHHHHSMemonophosphateHHHHSEtmonophosphateHHHHS-cyclopropylmonophosphateHHHHFmon...

example 3

Preparation of 3′-C-methylriboadenine

[0473] The title compound can be prepared according to a published procedure (R. F. Nutt, M. J. Dickinson, F. W. Holly, and E. Walton, “Branched-chain sugar nucleosides. m. 3′-C-methyladenine”, J. Org. Chem. 1968, 33, 1789-1795) (Scheme 9).

[0474] In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula III are prepared.

[0475] wherein:

R1R2R3X1X2YHHHHHHHHHHHNH2HHHHHNH-cyclopropylHHHHHNH-methylHHHHHNH-ethylHHHHHNH-acetylHHHHHOHHHHHHOMeHHHHHOEtHHHHHO-cyclopropylHHHHHO-acetylHHHHHSHHHHHHSMeHHHHHSEtHHHHHS-cyclopropylHHHHHFHHHHHClHHHHHBrHHHHHImonophosphateHHHHNH2monophosphateHHHHNH-acetylmonophosphateHHHHNH-cyclopropylmonophosphateHHHHNH-methylmonophosphateHHHHNH-ethylmonophosphateHHHHOHmonophosphateHHHHO-acetylmonophosphateHHHHOMemonophosphateHHHHOEtmonophosphateHHHHO-cyclopropylmonophosphateHHHHSHmonophosphateHHHHSMemonophosphateHHHHSEtmonophosphateHHHHS-cyclopropylmonophosphateHH...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Description

[0001] This invention is in the area of pharmaceutical chemistry, and is in particular, is a compound, method and composition for the treatment of hepatitis C virus. This application claims priority to U.S. provisional application No. 60 / 206,585, filed on May 23, 2000.FIELD OF THE INVENTION BACKGROUND OF THE INVENTION [0002] The hepatitis C virus (HCV) is the leading cause of chronic liver disease worldwide. (Boyer, N. et al. J. Hepatol. 32:98-112, 2000). HCV causes a slow growing viral infection and is the major cause of cirrhosis and hepatocellular carcinoma (Di Besceglie, A. M. and Bacon, B. R., Scientific American, October: 80-85, (1999); Boyer, N. et al. J Hepatol. 32:98-112, 2000). An estimated 170 million persons are infected with HCV worldwide. (Boyer, N. et al. J. Hepatol. 32:98-112, 2000). Cirrhosis caused by chronic hepatitis C infection accounts for 8,000-12,000 deaths per year in the United States, and HCV infection is the leading indication for liver transplant. [0003]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/513A61K31/52C07D473/18A61K31/522A61K31/7068A61K31/7072A61K31/7076A61K31/708A61P1/16A61P31/12A61P31/14C07D405/04C07D473/30C07D473/34C07H19/04C07H19/06C07H19/067C07H19/073C07H19/10C07H19/16C07H19/167C07H19/173C07H19/20
CPCA61K31/708C07H19/04C07H19/06C07H19/10C07H19/16C07H19/20A61K45/06A61K31/7056A61K38/21A61K31/7068A61K31/7072A61K31/7076G03C1/0051A61P1/16A61P31/12A61P31/14A61P31/20A61P43/00C07H19/167
Inventor SOMMADOSSI, JEAN-PIERRELACOLLA, PAULO
Owner SOMMADOSSI JEAN PIERRE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap